<DOC>
	<DOCNO>NCT00978107</DOCNO>
	<brief_summary>This trial phase I , open-label , dose-escalating study safety percutaneous intra-tumoral injection TG4023 ( MVA-FCU1 ) combine systemic administration 5-fluorocytosine patient primary secondary hepatic tumor .</brief_summary>
	<brief_title>Trial TG4023 Combined With Flucytosine Liver Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Flucytosine</mesh_term>
	<criteria>Patients advance disease without standard care treatment option : hepatic metastasis colorectal cancer ( CRC ) cancer Hepatocellular carcinoma ( HCC ) At least one unresectable target tumor locate liver , measure 25 cm accessible IT administration TG4023 amenable radiological measurement use RECIST , Weight ≤ 100 kg , Patients stable disease , discontinue chemotherapy intolerance , ECOG performance status ≤ 2 , Life expectancy ≥ 3 month , Hematology : Absolute neutrophil count &gt; 1,500/mm3 , Hemoglobin &gt; 9g/dL , Platelet count &gt; 100,000/mm3 , Prothrombin time international normalize ratio ( INR ) ≤ 2 ; partial thromboplastin time ≤ 1.66 time upper limit normal ( ULN ) , Biochemistry : Total bilirubin ≤ 3 x ULN , Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase 5.0 x ULN , Creatinin clearance ≥ 40 mL/min , Total albumin ≥ 30 g/L , Antivitamin K anticoagulant switch lowmolecular weight heparin prior TG4023 injection , Signed , write Independent Ethics Committee ( IEC ) approve informed consent . ChildPugh stage C hepatic insufficiency , Impaired renal function ( creatinin clearance &lt; 40 mL/min ) , Known deficiency dihydropyrimidine dehydrogenase ( DPD ) total DPD deficiency diagnose baseline patient previously treat 5FUrelated compound , Ascites , Brain metastasis , Significant impairment gastrointestinal ( GI ) tract absorption capacity , total gastrectomy , gastric mucosal atrophy , extensive intestinal resection malabsorption disease treat oral 5FC , History bleed disorder , Pregnant breastfeed woman , Human Immunodeficiency Virus ( HIV ) positive , Chronic use immunodepressants within 4 week prior TG4023 injection immunedepressed patient , Hypersensitivity 5FC , Hypersensitivity egg protein , Concomitant previous chemotherapy target therapy within 4 week prior TG4023 injection last treatment bevacizumab ( Avastin® ) within 2 month prior TG4023 injection , Concomitant treatment antiinflammatory drug : systemic corticosteroid nonsteroidal antiinflammatory drug ( NSAIDs ) , Prior gene therapy , Prior participation research protocol involve IMP within 2 month prior TG4023 injection , Major surgery within 6 week TG4023 injection ,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Hepatic tumor</keyword>
	<keyword>Metastatic colorectal cancer</keyword>
</DOC>